This Week’s Biopharma News: Wave of Antibody Approvals - Takeaway - MDSpire
From the Journals
Clinical Guidelines
Conference News

This Week’s Biopharma News: Wave of Antibody Approvals

FDA expands Tzield, EU clears Dupixent, and Health Canada approves denosumab antibody biosimilars

  • April 28, 2026

  • 5 min

Share

  • 1

    Teplizumab approved for children as young as 1 for type 1 diabetes.

  • 2

    Aim is to delay progression to stage 3 disease.

  • 3

    FDA shifts toward human-relevant testing over animal models.

  • 4

    Tozorakimab significantly reduces COPD exacerbations.

  • 5

    Dupixent approved for children with chronic hives.

  • 6

    Biocon's denosumab biosimilars gain Health Canada approval.

  • 7

    Moderna's mCOMBRIAX combines flu and COVID vaccines.

Original Source(s)

This Week’s Biopharma News: Wave of Antibody Approvals

  • April 28, 2026

Related Content

Bridging the Diabetic Eye Care Divide

Study evaluates eye care utilization of diabetic patients in Northern Uganda, spotlighting limited health literacy and awareness as determining factors in care

  • May 1, 2026

  • 3 min
Digital Twins for Rare Diseases

AI-driven models address data gaps in rare disease research and diagnostics

  • April 20, 2026

  • 5 min
BMI-Adjusted Grip Strength and Sarcopenia in Prediabetes

Researchers report 8% prevalence of probable sarcopenia and a 96.4% specificity cutoff for BMI-adjusted grip strength.